|3 Hrs 0 min over 56 days
|3.0 AMA PRA Category 1 Credits™, 3.0 ANCC
The purpose of this curriculum is to improve the performance of learners to apply practice-changing clinical data and expert recommendations in order to optimize clinical outcomes with BCMA-targeted therapies for their patients with relapsed/refractory multiple myeloma. This will be achieved with the establishment of meaningful small group interactions among clinicians and a variety of collaborative educational experiences.
This Baseline Assessment is designed to gauge your knowledge of BCMA-targeted therapies prior to the program education. You will be asked these questions again after you have completed the education.
In this brief text module, Dr. Peter Voorhees discusses why BCMA is a useful target in relapsed/refractory myeloma and examines the 2 FDA-approved agents--belantamab mafodotin and idacabtagene vicleucel--targeting BCMA.
Dr. Nina Shah spotlights the many BCMA-targeting antibody-drug conjugates and CAR T-cell therapies currently under investigation for patients with heavily pretreated myeloma.
Now that you have learned more about BCMA-targeting therapies, we ask you to please revisit the questions you addressed at the start of this program.
Please join me for a brief kick-off where you'll have a chance to greet other group members and discuss our collective goals and priorities for the next few weeks. I’m really looking forward to seeing you.
This live discussion will offer an interactive approach to providing optimal care with BCMA-targeted therapy for patients with relapsed/refractory multiple myeloma.
In this discussion, we will review the patient cases and group tasks assigned, and how the findings can apply to improving care for patients with heavily pretreated multiple myeloma.
The following case challenge presents Mr. Simmons, an elderly patient with multiple-refractory MM. The group objective of this segment is to explore all aspects of MM management with this patient.
This case challenge presents Mrs. Williams, a younger patient who had achieved MRD negativity with stem cell transplant but has since progressed on multiple therapies. The group objective of this segment is to discuss optimal treatment and AE management.
Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.